专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明专利

CO2022015033A2 Composiciones y métodos para tratar la enfermedad intestinal inflamatoria mediante el uso de inhibidor de ccr9 y anticuerpos bloqueadores anti-il-23 未知
公开(公告)号：CO2022015033A2
公开(公告)日：2022-10-31
申请号：CO2022015033
申请日：2022-10-21
申请人： CHEMOCENTRYX INC
发明人： ZENG YIBIN , CAMPBELL JAMES , CHARO ISRAEL , SCHALL THOMAS , SINGH RAJINDER , ZHANG PENGLIE
IPC分类号： A61K31/18 , A61K31/4155 , A61K31/498 , A61P1/04 , C07D231/14 , C07D237/00
摘要： En la presente descripción se proporcionan composiciones, métodos y kits para tratar la enfermedad intestinal inflamatoria (EII), tal como la enfermedad de Crohn y la colitis ulcerosa en un mamífero que lo necesite. El método incluye administrar a un sujeto con EII una terapia combinada que contiene una cantidad terapéuticamente eficaz de un compuesto inhibidor del receptor de quimiocinas 9 (CCR9) y una cantidad terapéuticamente eficaz de un anticuerpo anti-IL-23. También se proporciona en la presente descripción un kit que contiene el compuesto inhibidor de CCR9 y el anticuerpo anti-IL-23.

22. 发明专利

AR122407A1 COMPOSICIONES Y MÉTODOS PARA TRATAR LA INFLAMACIÓN INTESTINAL USANDO UN INHIBIDOR DE CCR9 Y ANTICUERPOS DE BLOQUEO ANTI-IL-23 未知
公开(公告)号：AR122407A1
公开(公告)日：2022-09-07
申请号：ARP210100819
申请日：2021-03-31
申请人： CHEMOCENTRYX INC
发明人： CAMPBELL JAMES , CHARO ISRAEL , SCHALL THOMAS , SINGH RAJINDER , ZENG YIBIN , ZHANG PENGLIE
IPC分类号： A61K31/18 , A61K31/4155 , A61K31/4402 , A61K31/4709 , A61K31/498 , A61K39/395 , A61P1/04 , C07D231/14 , C07D237/00 , C07K16/24 , C07K16/28
摘要： En la presente descripción se proporcionan composiciones, métodos y kits para tratar la inflamación intestinal (IBD) tal como la enfermedad de Crohn y la colitis ulcerosa en un mamífero que lo necesita. El método incluye administrar a un sujeto con IBD una terapia de combinación que contiene una cantidad terapéuticamente eficaz de un compuesto inhibidor del receptor 9 quimiocina (CCR9) y una cantidad terapéuticamente eficaz de un anticuerpo anti-IL-23. En la presente descripción también se proporciona un kit que contiene el compuesto inhibidor de CCR9 y el anticuerpo anti-IL-23. Reivindicación 1: Un método para tratar o reducir el desarrollo de la inflamación intestinal en un mamífero, dicho método comprende administrar una cantidad adecuada de un inhibidor de CCR9 con un anticuerpo de bloqueo anti-IL-23 o anti-receptor de IL-23, en donde el inhibidor del receptor de quimiocina CCR9 es un compuesto que tiene la fórmula (1) o una sal de este, donde R¹ se selecciona del grupo que consiste en alquilo C₂₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, alquilamino C₁₋₈ sustituido o no sustituido, y heterociclilo C₃₋₁₀ sustituido o no sustituido, y; R² es H, F, Cl, o alcoxi C₁₋₈ sustituido o no sustituido; o R¹ y R² junto con los átomos de carbono a los que están unidos forman un anillo carbocíclico no aromático o un anillo heterocíclico; R³ es H, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, o halo; R⁴ es H o F; R⁵ es H, F, Cl, o -CH₃; R⁶ es H, halo, -CN, -CO₂Rᵃ, -CONH₂, -NH₂, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, o aminoalquilo C₁₋₈ sustituido o no sustituido; Rᵃ es H o alquilo C₁₋₈ sustituido o no sustituido; donde R⁵ y R⁶ pueden formar juntos un anillo carbocíclico; L es un enlace, -CH₂-, o -CH(CH₃)-; cada uno de A¹, A², A³, A⁴, A⁵, A⁶, A⁷, y A⁸ se selecciona independientemente del grupo que consiste en N, N-O, y -CR⁸-; donde al menos uno y no más de dos de A¹, A², A³, A⁴, A⁵, A⁶, A⁷, y A⁸ son N o N-O; R⁸ se selecciona cada uno independientemente del grupo que consiste en H, halo, -CN, -OH, oxo, alquilo C₁₋₈ sustituido o no sustituido, alcoxi C₁₋₈ sustituido o no sustituido, y -NR²⁰R²¹, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, y heterociclilo sustituido o no sustituido; y R²⁰ y R²¹ son cada uno independientemente H o alquilo C₁₋₈ sustituido o no sustituido.

23. 发明专利

AU2020386066A1 Compositions and methods for treating CCR9-mediated diseases using CCR9 inhibitor and anti-TNF-alpha blocking antibodies 未知
公开(公告)号：AU2020386066A1
公开(公告)日：2022-06-09
申请号：AU2020386066
申请日：2020-11-20
申请人： CHEMOCENTRYX INC
发明人： SCHALL THOMAS , CAMPBELL JAMES J
IPC分类号： A61K31/426 , A61P35/00 , C07D277/42
摘要： Provided herein are compositions, methods and kits for a CCR9-mediated disease in a mammal in need thereof. The method include administering to a subject with a CCR9-mediated disease a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-TNFα antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-TNFα antibody.

24. 发明专利

AU2017363299A1 Method of treating focal segmental glomerulosclerosis 未知
公开(公告)号：AU2017363299A1
公开(公告)日：2019-06-13
申请号：AU2017363299
申请日：2017-11-22
申请人： CHEMOCENTRYX INC
发明人： MIAO ZHENHUA , SCHALL THOMAS , SINGH RAJINDER
IPC分类号： A61K31/18 , A61K31/437 , A61K31/44 , C07D213/24 , C07D213/30 , C07D213/44
摘要： A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

25. 发明专利

SG11201808626WA REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS 未知
公开(公告)号：SG11201808626WA
公开(公告)日：2018-10-30
申请号：SG11201808626W
申请日：2017-04-06
申请人： CHEMOCENTRYX INC
发明人： CHARO ISRAEL , JUNG HEIYOUN , SCHALL THOMAS , ZHANG PENGLIE
IPC分类号： A61K31/4178 , A61K31/4155 , C07D471/04
摘要： The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.

26. 发明专利

CA3044621A1 METHOD OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS 未知
公开(公告)号：CA3044621A1
公开(公告)日：2018-05-31
申请号：CA3044621
申请日：2017-11-22
申请人： CHEMOCENTRYX INC
发明人： MIAO ZHENHUA , SCHALL THOMAS , SINGH RAJINDER
IPC分类号： A61K31/18 , A61K31/437 , A61K31/44 , C07D213/24 , C07D213/30 , C07D213/44
摘要： A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

27. 发明专利

DK1871804T3 Antistoffer, der binder CCX-CKR2 未知
公开(公告)号：DK1871804T3
公开(公告)日：2013-12-02
申请号：DK06758551
申请日：2006-04-19
申请人： CHEMOCENTRYX INC
发明人： HOWARD MAUREEN , SCHALL THOMAS
IPC分类号： C07K16/28 , A61K39/395 , C07H21/04 , C07K17/00 , C12P21/06 , G01N33/68

28. 发明专利

AU2005209921B2 Methods and compositions for modulating angiogenesis 未知
公开(公告)号：AU2005209921B2
公开(公告)日：2011-04-07
申请号：AU2005209921
申请日：2005-02-02
申请人： CHEMOCENTRYX INC
发明人： SUMMERS BRETTON , HOWARD MAUREEN , MIAO ZHENHUA , BURNS JENNIFER , SCHALL THOMAS , WANG YU
IPC分类号： C07K16/28 , A61K38/00 , A61K38/17 , A61K38/19 , A61K39/395
摘要： The present invention provides method and compositions for modulating angiogenesis.

29. 发明专利

AT384041T 未知
公开(公告)号：AT384041T
公开(公告)日：2008-02-15
申请号：AT03816012
申请日：2003-11-18
申请人： CHEMOCENTRYX INC
发明人： UNGASHE SOLOMON , WEI ZHENG , WRIGHT J , PENNELL ANDREW , PREMACK BRETT , SCHALL THOMAS
IPC分类号： C07C311/21 , A61K31/18 , A61P29/00 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要： Compounds of formula (I) (in which the variables L, X, Y and Z are as defined in the claims) are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulphonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

30. 发明专利

CA2511242A1 INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR 未知
公开(公告)号：CA2511242A1
公开(公告)日：2004-07-15
申请号：CA2511242
申请日：2003-12-22
申请人： CHEMOCENTRYX INC
发明人： MELIKIAN ANITA , BURNS JENNIFER , SCHALL THOMAS , MCMASTER BRIAN E , WRIGHT JOHN J
IPC分类号： C07D207/06 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/14 , C07D211/42 , C07D211/56 , C07D241/04 , C07D241/42 , C07D295/13 , C07D401/04 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D295/04 , C07D407/12 , C07D211/26
摘要： Pharmaceutical compositions containing organic compounds of formula (I) or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式